• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine, Inc. - Common Stock (NQ:EDIT)

    3.750 -0.050 (-1.32%)
    Streaming Delayed Price Updated: 12:25 PM EDT, Oct 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,122,429
    Open 3.820
    Bid (Size) 3.750 (38)
    Ask (Size) 3.760 (3)
    Prev. Close 3.800
    Today's Range 3.680 - 3.905
    52wk Range 0.9101 - 4.070
    Shares Outstanding 81,632,619
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend
    Editas Medicine (EDIT) stock shows strong technical uptrends and explosive 597% revenue growth, making it a top pick for momentum investors. 
    Via Chartmill
    Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +186.3%
    +186.3%
    1 Month
    +34.4%
    +34.4%
    3 Month
    +47.6%
    +47.6%
    6 Month
    +275.0%
    +275.0%
    1 Year
    +16.8%
    +16.8%

    More News

    Read More
    My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
    Via Benzinga
    Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
    Via Benzinga
    Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine to Participate in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Why Editas Medicine Stock Was Skyrocketing This Week
    Via The Motley Fool
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Top movers in Wednesday's session
    Via Chartmill
    Wednesday's session: gap up and gap down stocks
    Via Chartmill
    Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss
    Via Chartmill
    Editas Medicine Announces Second Quarter 2025 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Can This Beaten-Down Stock Bounce Back?
    Via The Motley Fool
    Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
    Via The Motley Fool
    Topics Workforce
    2 Beaten-Down Stocks to Avoid
    Via The Motley Fool
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
    Via Benzinga
    Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
    Via The Motley Fool
    Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
    Via Investor's Business Daily
    Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
    From Editas Medicine, Inc.
    Via GlobeNewswire
    1 Stock Down 97% That Could Double, According to Wall Street
    Via The Motley Fool
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Editas Medicine: A Cautionary Tale for Investors
    Via The Motley Fool
    Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Editas Medicine, Inc. - Common Stock publicly traded?
    Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
    What exchange does Editas Medicine, Inc. - Common Stock trade on?
    Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
    The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
    What is the current price of Editas Medicine, Inc. - Common Stock?
    The current price of Editas Medicine, Inc. - Common Stock is 3.750
    When was Editas Medicine, Inc. - Common Stock last traded?
    The last trade of Editas Medicine, Inc. - Common Stock was at 10/07/25 12:25 PM ET
    What is the market capitalization of Editas Medicine, Inc. - Common Stock?
    The market capitalization of Editas Medicine, Inc. - Common Stock is 306.12M
    How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
    Editas Medicine, Inc. - Common Stock has 306M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.